Sanofi-Aventis is considering making acquisitions in order to catch up in the field of monoclonal antibodies, pharmaceutical head Hanspeter Spek told Financial Times Deutschland.
"Monoclonal antibodies are our weak point, we are running very late there,"Spek said. He added that he hopes it is not too late to catch up and that an acquisition could put things right.
Source
No comments:
Post a Comment